Key result
Percutaneous implantation of a left atrial appendage occluder was feasible, achieving successful implantation in 95.7% of patients with no occurrence of death or stroke over a mean 31.17 months.
Why the study?
The authors aimed to describe the feasibility, safety, and outcomes of percutaneous LAA closure with an occluder device, and evaluate residual contrast leak on CT imaging.
Is percutaneous left atrial appendage closure using an occluder device feasible and safe in patients with atrial fibrillation?
Cohort
No
Is percutaneous left atrial appendage closure using an occluder device feasible and safe in patients with atrial fibrillation?
Percutaneous left atrial appendage occlusion demonstrates high procedural success and safety in a real-world cohort, supporting its use in patients with atrial fibrillation who experience bleeding on oral anticoagulation.
Single-center LAA closure series supports procedural feasibility; leaves open clinical relevance of residual CT leaks.
Background: Left atrial appendage (LAA) is the main source of thrombus formation, and occlusion of this structure decreases the risk of stroke in patients with atrial fibrillation. Objectives: We aimed to describe the feasibility, safety and outcomes of percutaneous LAA closure using an occluder device, and to evaluate residual LAA contrast leak detected on computed tomography (CT) imaging in patients who underwent implantation in our institution. Methods: Consecutive patients of Taipei Veterans General Hospital who underwent percutaneous implantation of an LAA occluder (LAAO) were retrospectively collected and analyzed. Results: -VASc score of 4 (1-7). The most frequent indication for intervention was bleeding while on oral anticoagulation treatment. After a mean follow-up of 31.17 ± 25.10 months, successful device implantation was achieved in 95.7% of the patients. There was no occurrence of death, stroke, device embolization, acute ST elevation myocardial infarction, major bleeding requiring invasive treatment or blood transfusion, inguinal hematoma or major bleeding related to antiplatelet therapy. One patient had cardiac tamponade, 1 had intra-procedural thrombus formation, 1 had impingement of mitral valve leaflet, and 1 had device-related thrombosis. Of 12 patients who underwent CT post- implantation, 6 had residual contrast leak into the LAA, one third of those who had peri-device leak. Conclusions: Percutaneous implantation of an LAAO appeared to be feasible with a low risk of major complications.
No takes yet. Share an insight, caveat, or question.
Lugtu et al. (2022) conducted a cohort in Atrial fibrillation. Percutaneous left atrial appendage occluder (LAAO) was evaluated on Successful device implantation. Percutaneous implantation of a left atrial appendage occluder was feasible, achieving successful implantation in 95.7% of patients with no occurrence of death or stroke over a mean 31.17 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: